Pooja Khatri, MD, MSc
Albert E. Kent Professor of Neurology; Chair of NeurologyCards
About
Research
Publications
2026
Using radiological brain health to predict recurrence after ischemic stroke and transient ischemic attack: A population-based study.
Robinson D, Khatri P, Sucharew H, Williamson B, Khandwala V, Maloney T, Wang L, Gaskill-Shipley M, Cornelius R, Tomsick T, Wang D, Horn P, Gangatirkar S, Carrozzella J, Stanton R, Kleindorfer D, Kissela B, Vagal A. Using radiological brain health to predict recurrence after ischemic stroke and transient ischemic attack: A population-based study. Neurology Open Access 2026, 2 PMID: 42293258, PMCID: PMC13256317, DOI: 10.1212/wn9.0000000000000090.Peer-Reviewed Original ResearchBrain healthHigh riskStroke recurrenceSecondary prevention effortsMeasures of brain healthMarkers of brain healthPopulation-based studyWhite matter hyperintensitiesPrediction of stroke recurrenceIschemic strokeStroke survivorsRecurrent stroke eventsStroke eventsPrevention effortsRisk of recurrenceStroke patientsNontraditional risk factorsPrediction model of recurrenceDifferent hospitalsStudy populationRisk factorsHealthNeuroimaging markersClinical factorsTransient ischemic attackRelation between Time from Onset to Randomization and Benefit Magnitude in Recent Clinical Trials of Thrombectomy for Patients with Large Ischemic Cores.
Gajewski B, Gajewski K, Khatri P, Saver J, Johnston K, Beall J, Elm J. Relation between Time from Onset to Randomization and Benefit Magnitude in Recent Clinical Trials of Thrombectomy for Patients with Large Ischemic Cores. Annals Of Indian Academy Of Neurology 2026 PMID: 42262801, DOI: 10.4103/aian.aian_72_26.Peer-Reviewed Original ResearchEndovascular thrombectomyMedical managementClinical trialsOnset-to-treatment timeBenefit of endovascular thrombectomyUtility-weighted modified Rankin scaleStudy-level dataAbsolute treatment effectMedian timeTreatment delayRandomized trialsRankin ScaleSymptom onsetTreatment effectsIschemic coreAcute strokeDeviance information criterionTrial designThrombectomyPatientsBenefit magnitudeTrialsNeuroGleam: Illuminating Small Vessel Disease Detection Through Deep Learning Based Segmentation of Brain MRI White Matter Hyperintensities
Iyer B, Williamson B, Surya Prasath V, Aronow B, Khatri P, Sucharew H, Khandwala V, LaPorta J, Wang L, Cornelius R, Gaskill-Shipley M, Tomsick T, Wang D, Maloney T, Horn P, Carrozzella J, Kissela B, Vagal A. NeuroGleam: Illuminating Small Vessel Disease Detection Through Deep Learning Based Segmentation of Brain MRI White Matter Hyperintensities. Lecture Notes In Computer Science 2026, 16446: 508-521. DOI: 10.1007/978-3-032-18474-0_35.Peer-Reviewed Original ResearchDeep learningMedical Image ComputingComputer Assisted InterventionDomain adaptationGeneralization gapChallenge datasetTransfer learningDL architecturesRobust deploymentImage computationBayesian optimizationLoss objectivesDesign choicesAverage volume differenceSingle-modeDisease detectionAssisted InterventionsLesion-wiseArchitectureComputerDiceHRNetMICCAIMRI seriesBase segmentsNeurologist Compensation and Productivity From 2013 to 2023 in the United States
de Havenon A, Littig L, Krothapalli N, Hill C, Khatri P, Burke J, Callaghan B. Neurologist Compensation and Productivity From 2013 to 2023 in the United States. Neurology 2026, 106: e214643. PMID: 41662619, DOI: 10.1212/wnl.0000000000214643.Peer-Reviewed Original ResearchConceptsMedical specialtiesFull-time effortPractice locationFamily medicineEmergency medicineHospital systemGroup employmentReimbursement modelsPhysician compensationInternal medicineTertiary outcomesVascular neurologistsUnited StatesSecondary outcomesPrimary outcomeMedical groupSpecialtyFull-timeNeurologistsNeurocritical careHospitalWRVUOrthopaedic surgeryOutcomesPediatricRecombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Broderick J, Naidech A, Elm J, Toyoda K, Dowlatshahi D, Demchuk A, Khatri P, Steiner T, Bath P, Audebert H, Vagal A, Yoshimura S, Mayer S, Wang L, Sabagha N, Mocco J, Molina C, Aviv R, Stinson E, Quadri S, Carrozzella J, Huynh T, Phan A, Beall J, Davis I, Sakai N, Ohta T, Yokosawa M, Hara T, Sangha N, Morita K, Tse M, Streib C, Miyashita F, Silva Y, Nagakane Y, Gheorghiu T, Sun C, Hirano T, Poli S, Izumo T, Fukuda-Doi M, Ihara M, Koga M, Buck B, Walsh K, Spokovny I, Grotta J, Investigators F, Broderick J, Grotta J, Naidech A, Elm J, Toyoda K, Demchuk A, Dowlatshahi D, Molina C, Steiner T, Bath P, Audebert H, Mocco J, Khatri P, Vagal A, Aviv R, Mayer S, Janis S, Yoshimura S, Quadri S, Stinson E, Sabagha N, Wang L, Carrozzella J, Huynh T, Phan A, Beall J, Davis I, Sakai N, Ohta T, Yokosawa M, Hara T, Sangha N, Morita K, Tse M, Streib C, Miyashita F, Silva Y, Nagakane Y, Gheorghiu T, Sun C, Hirano T, Poli S, Izumo T, Fukuda-Doi M, Ihara M, Koga M, Buck B, Walsh K, Spokoyny I, Navalkele D, Fujinaka T, Fabregas J, Hicks W, Watanabe T, Yakushiji Y, Portela P, Jumaa M, Kansara A, Nolte C, Muccilli A, Martinez R, Rangel A, Schneider H, Kuwashiro T, Meyer B, Shoamanesh A, Gioia L, Liptrap E, Borczuk P, Gentile N, Kaur S, Shownkeen H, Mathew J, Purrucker J, Fujimoto S, Marulanda-Londono E, Ezzeddine M, Poyraz F, Nour M, Khanna A, Ng L, Panagos P, Appleton J, Kallmuenzer B, Khosravani H, Grandhi R, Vajda P, Singh V, Shah J, Sivakumar S, Zimmerman L, Gordon E, Jackson R, Brogan M, Rivet D, Grewal P, Hannawi Y, Mansour A, Jahromi B, Silver B, Scharf E, Singh N, Natarajan I, Purroy F. Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet 2026, 407: 773-783. PMID: 41653933, PMCID: PMC13005960, DOI: 10.1016/s0140-6736(26)00097-8.Peer-Reviewed Original ResearchConceptsRecombinant factor VIIaLife-threatening thromboembolic complicationsSpontaneous intracerebral haemorrhageIntraventricular haemorrhagePhase 3 trialPlacebo groupPrimary clinical outcome measuresFactor VIIaIntracerebral haemorrhageDouble-blindPlacebo-ControlledThromboembolic complicationsLateral ventricleTreated with study medicationFunctional outcomesAdministration of study drugInterim analysisBaseline ICH volumePreplanned interim analysisLife-threatening thromboembolic eventsIntervention groupStroke onsetGlasgow Coma Scale scoreIntracerebral haemorrhage volumeIntention-to-treat analysisBlood pressure reduction and reperfusion therapy
Mistry E, Khatri P. Blood pressure reduction and reperfusion therapy. The Lancet Neurology 2026, 25: 124-125. PMID: 41579888, DOI: 10.1016/s1474-4422(26)00003-7.Peer-Reviewed Original ResearchLow-Intensity Monitoring for Mild-to-Moderate Acute Ischemic Stroke Is Cost Saving: Economic Evaluation for OPTIMISTmain
Xu L, Ouyang M, Atkins E, Summers D, Sui Y, Johnson B, Billot L, Malavera A, Faigle R, Muñoz-Venturelli P, Day D, Liu X, Li Q, Song L, Robinson T, González F, Urrutia-Goldsack F, Delcourt C, Nguyen H, Ton M, Liu H, Lindley R, Arauz A, Mercado A, Zaidi W, Khatri P, Wang X, Urrutia V, Jan S, Anderson C. Low-Intensity Monitoring for Mild-to-Moderate Acute Ischemic Stroke Is Cost Saving: Economic Evaluation for OPTIMISTmain. Stroke 2026, 57: 587-596. PMID: 41608808, DOI: 10.1161/strokeaha.125.053506.Peer-Reviewed Original ResearchConceptsLow intensity monitoringCost-saving thresholdsEconomic benefitsUnited KingdomMonitoring costsUnited StatesScenario analysisStandard careAcute ischemic strokeCost savingsEconomic evaluationProbability of cost savingsCost minimizationLow-intensity careSavingsCost-minimization analysisCountries2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association.
Prabhakaran S, Gonzalez N, Zachrison K, Adeoye O, Alexandrov A, Ansari S, Chapman S, Czap A, Dumitrascu O, Ishida K, Jadhav A, Johnson B, Johnston K, Khatri P, Kimberly W, Lee V, Leslie-Mazwi T, Mac Grory B, Madsen T, Menon B, Mistry E, Park S, Parker S, Pérez de la Ossa N, Reeves M, Saiz T, Scott P, Schwartzberg D, Sheth S, Sporns P, Times S, Tjoumakaris S, Wolfe S, Yaghi S, Leira E, Broderick J, Arauz A, Ardelt A, Bahouth M, Caulfield A, Derdeyn C, Dylla L, Frankel M, Fullerton H, Guerrero W, Jauch E, Kicielinski K, Labram Y, Lyden P, Marsh E, Meurer W, Mocco J, Pandey A, Rabinstein A, Rapp K, Richards C, Rocha M, Royan R, Samaniego E, Sangha N, Schirmer C, Simpkins A, Streib C, Tirschwell D, Zink E. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke 2026 PMID: 41582814, DOI: 10.1161/str.0000000000000513.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEarly in-hospital managementEarly management of patientsEvidence-based setManagement of patientsAmerican Heart Association/American Stroke AssociationAllied health professionalsEarly managementEvidence-based set of recommendationsPrehospital evaluationCare professionalsHealth professionalsSet of recommendationsHospital administratorsStroke AssociationManagement of complicationsAcute ischemic strokeCochrane LibraryManagement of hyperglycemiaDetermination of eligibilityAcute treatmentPediatric populationTreatment strategiesEndovascular thrombectomyComprehensive evidenceProfessionalsNeurointerventional Practice Change Following Distal Medium Vessel Occlusion Randomized Controlled Trials: A Survey
Aziz Y, Garcia R, Plummer P, Affan M, Staloch J, Castanon F, Reinhart C, Davis I, Sullivan R, Kussie P, Khandwala V, Vagal A, Siegler J, Pillajo J, Broderick J, Reed G, Elm J, Khatri P, Mistry E, Investigators O. Neurointerventional Practice Change Following Distal Medium Vessel Occlusion Randomized Controlled Trials: A Survey. Stroke Vascular And Interventional Neurology 2026, 6: e001965. PMID: 41503087, PMCID: PMC12771975, DOI: 10.1161/svin.125.001965.Peer-Reviewed Original ResearchSite principal investigatorsStroke teamPractice changeComprehensive stroke centerPrincipal investigatorTeam-based decision-makingStroke centersNational InstituteRandomized Controlled TrialsClinical teamDistal medium vessel occlusionEmail surveyControlled TrialsSurvey respondentsRCT resultsMechanical thrombectomySurvey responsesRCTsExpert feedbackSymptom severityTreatment decisionsMedium vessel occlusionsRandomized trialsStrokeTeamTen years of Central IRB review for an NIH-funded large clinical trial network by an academic IRB: The NIH StrokeNet experience
Linke M, Braggs-Brown A, Roll S, Mills K, Davis S, Broderick J, Khatri P. Ten years of Central IRB review for an NIH-funded large clinical trial network by an academic IRB: The NIH StrokeNet experience. Journal Of Clinical And Translational Science 2026, 10: e14. PMID: 41657754, PMCID: PMC12873484, DOI: 10.1017/cts.2025.10231.Peer-Reviewed Original Research
Clinical Care
Overview
Pooja Khatri, MD, MS, is chair of the Yale Medicine Department of Neurology, and chief of Neurology at Yale New Haven Hospital and the Yale New Haven Health System. She is a world-renowned expert in stroke care and research, and she is passionate about helping those with neurological conditions achieve the best possible outcomes.
Dr. Khatri reminds people who are concerned for themselves or a loved one with a neurological condition that treatments have advanced tremendously for many diseases of the brain and other parts of the nervous system. “People who have just gotten a new diagnosis don’t always realize how much care has changed in recent decades,” she says. “There are treatments available now that didn’t exist in the past.”
While there is still a lot to learn, Dr. Khatri says, “In my career, I’ve seen stroke go from a disease that we often couldn't do much about to a potentially reversible disease if the patient gets to the hospital fast enough.” (Patients who get to the hospital within hours of the first symptoms of an ischemic stroke may get a type of medicine called a thrombolytic, or "clot-busting," drug, or procedure called mechanical thrombectomy, or “clot extraction,” to improve their chances of recovery. Faster treatment gives the best chances of success.) She notes there also have been significant breakthroughs in preventing stroke, as well as the care of such conditions as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.
Dr. Khatri became interested in medicine at a young age. Her father, who dreamed of studying medical science but became an engineer instead, was a major influence on her decision to pursue medicine. As she got older, a pivotal moment came during a trip to India when she visited a town where the only available doctor was a veterinarian. That experience reinforced her determination to become a doctor and help people.
In addition to her work with patients, Dr. Khatri is a professor of neurology at Yale School of Medicine. She has significantly advanced the field of stroke therapy with research that spans acute stroke therapy, prevention of early stroke recurrence, development of radiological biomarkers, and clinical trial design. She has held multiple leadership positions in the United States and abroad. One of these positions, since 2013, has been codirector of the National Coordinating Center of StrokeNet, which is the main infrastructure for National Institutes of Health-funded multicenter stroke trials.
Clinical Specialties
Board Certifications
Vascular Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Latest Certification Date
- 2025
- Original Certification Date
- 2008
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Latest Certification Date
- 2015
- Original Certification Date
- 2005
News
News
- May 12, 2026
Khatri Elected to Membership in Association of American Physicians
- May 01, 2026Source: WTNH News 8
Warning signs of a stroke
- February 06, 2026
Khatri Honored by American Stroke Association at International Stroke Conference 2026
- February 04, 2026Source: Bioengineer.org
Eleven Leading Stroke Researchers Honored for Groundbreaking Contributions to Brain Health and Science
Get In Touch
Contacts
Yale School of Medicine
Lippard Laboratory for Clinical Investigation (LLCI), 15 York Street
New Haven, CT 06510
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.